Cellular Factor Solution Compositions for Wound Healing

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current protein-based therapeutic agents, such as cytokines and growth factors, fail to administer physiologically relevant levels effectively due to high doses and instability issues, leading to incomplete recreation of physiological niches and increased risk of protein denaturation.

Innovation Solution

Development of novel cellular factor-containing solution compositions (CFS) and sustained-release cellular factor-containing solution compositions (SR-CFS) that mimic the complex and unique combination of cytokines and growth factors found in biological niches, using amnion-derived cellular cytokine solutions with specific concentrations of VEGF, TGFβ2, Angiogenin, PDGF, TIMP-1, and TIMP-2, and methods for pooling and sustained-release formulation to maintain consistent therapeutic levels.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If high doses of individual cytokines and growth factors are administered, then therapeutic effect is enhanced, but protein denaturation risk increases and physiological balance is disturbed

Engineering Contradiction:
Improvetherapeutic effectVSAvoidprotein denaturation
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent combines multiple cytokines and growth factors (PDGF-BB, GM-CSF, HGH, and others) into a single composition that mimics the complex physiological niche. This merging approach allows delivery of physiologically relevant combinations at appropriate concentrations rather than high doses of single factors, reducing denaturation risk while maintaining therapeutic efficacy through synergistic interactions.

Inventive Principle:
Principle #5Merging (Combining)

Solution Approach 2:

The invention changes the concentration parameters from high single-factor doses to physiologically relevant low-level combinations. The composition delivers multiple factors at concentrations that mimic in vivo levels, fundamentally altering the dosing paradigm to reduce protein stress and denaturation while achieving therapeutic effects through coordinated action of multiple factors.

Inventive Principle:
Principle #35Parameter changes

2Duration of action of moving object

If sustained-release formulations are developed, then therapeutic levels are maintained over time, but formulation complexity increases

Engineering Contradiction:
Improvetherapeutic level maintenanceVSAvoidformulation complexity
Core Design Contradiction:
Duration of action of moving objectVSDevice complexity

Solution Approach 1:

The composition serves multiple functions simultaneously: it provides sustained-release delivery, maintains physiologically relevant concentrations of multiple factors, and mimics the complex physiological niche. The single composition integrates what would otherwise require multiple separate delivery systems, reducing overall complexity while achieving sustained therapeutic effects.

Inventive Principle:
Principle #6Universality (Multi-functionality)

3Reliability

If complex combinations of cytokines and growth factors are used, then physiological niche recreation is improved, but manufacturing precision requirements increase

Engineering Contradiction:
Improvephysiological niche recreationVSAvoidconcentration control
Core Design Contradiction:
ReliabilityVSManufacturing precision

Solution Approach 1:

The patent uses cell culture systems to pre-assemble the complex combination of cytokines and growth factors in physiologically relevant proportions. The biological system naturally produces and secretes multiple factors at appropriate concentrations, performing the complex mixing and concentration adjustment beforehand, which simplifies downstream manufacturing and quality control.

Inventive Principle:
Principle #10Preliminary action

Data Source

PatentEP2185197B1Novel cellular factor- containing solution compositions and their use for treating wounds
Publication Date: 2018.10.17 STEMNION

AI summary

The invention is directed to novel cellular factor-containing solution compositions (referred to herein as "CFS" compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as "SR-CFS" compositions), methods of making such novel compositions and uses thereof.